Novel Therapeutic Approach for Human T-cell Malignancies

Condition(s) studied

Investigational drug(s) / intervention(s)

Translation analysis: Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.

Study summary

This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.

Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined.

The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.

Eligibility

Primary outcome measure(s)

• Primary outcome — Through study completion, an average of 2 years
  Response of leukemic cells to treatments that remodulate redox state and apoptosis from a molecular point of view, ex vivo,through the development of a multidimensional approach aimed at reducing the chemoresistance of T neoplasms

Trial sites (2)

More Istituto Oncologico Veneto IRCCS trials in Italy